OakChart

Century Therapeutics Inc

IPSCHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 2:03 PM ET

1.71+0.03 (1.58%)
2026-11-11 20:03 CET
Market cap
304.21 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-109.79 USD m
Free cash flow, TTM
-88.07 USD m
EPS diluted, TTM
-0.90
P/E
-
Compare

Price

IPSC against its 20, 50 and 200-day averages
2050200beatmiss
1.502.002.508.5M17.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IPSCclose 1.7120-day 1.5550-day 1.66200-day 2.071.71

43.8% under the 52-week high of 3.04 on 10 Mar 2026. 52-week low 0.44 on 17 Nov 2025. Last 15 sessions, 38.7% high to low

Profile

IPSC
52-week range, 49% of the way up
0.443.04

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

IndexRUT
Employees78
IPOJun 18, 2021
Beta1.75
ATR, 14d0.16
Rel volume0.24
Short float26.04%
Insider own32.08%
Inst own65.90%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap309.01M
Enterprise Value227.97M
Income-109.79M
Sales0.00M
Book/sh1.29
Cash/sh0.66
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees78
IPOJun 18, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.33
P/C2.58
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio8.28
Current Ratio8.28
Debt/Eq0.17
LT Debt/Eq0.15
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.90
EPS next Y-0.45
EPS next Q-0.12
EPS this Y-274.29%
EPS next Y14.44%
EPS next 5Y-
EPS past 3/5Y63.45% 35.31%
Sales past 3/5Y175.88% -
EPS Y/Y TTM-219.52%
Sales Y/Y TTM-100.00%
EPS Q/Q55.50%
Sales Q/Q-
EarningsAug 12 BMO
EPS/Sales Surpr.-54.55% -

Ownership

Insider Own32.08%
Insider Trans-0.02%
Inst Own65.90%
Inst Trans11.12%
ROA-38.41%
ROE-49.65%
ROIC-41.12%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2010.14%
SMA502.68%
SMA200-17.52%
Trades-

Technical

Shs Outstand180.55M
Shs Float122.98M
Short Float26.04%
Short Ratio44.46
Short Interest32.03M
52W High3.04 -43.87%
52W Low0.44 292.30%
Volatility15.08% 11.60%
ATR (14)0.16
RSI (14)55.37
Beta1.75
Rel Volume0.24
Avg Volume720.34K
Volume124,909

Performance

Perf Week2.19%
Perf Month23.66%
Perf Quarter-11.58%
Perf Half Y-25.15%
Perf YTD71.54%
Perf Year202.95%
Perf 3Y32.29%
Perf 5Y-91.85%
Perf 10Y-
Recom1.33
Target Price5.12
Prev Close1.68
Price1.71
Change %1.58%

Analyst ratings

latest 10 of 12
DateActionAnalystRating changeTargetImplied
May 27, 2026InitiatedMMizuhoOutperform$8+368.8%
Feb 25, 2026InitiatedTTD CowenBuy
Aug 08, 2024InitiatedRRodman & RenshawBuy$6+251.6%
Aug 28, 2023DowngradeJJP MorganOverweight → Neutral$28 → $5+193.0%
Dec 27, 2022InitiatedCChardan Capital MarketsBuy$19+1,013.4%
Oct 31, 2022InitiatedGGuggenheimBuy$15+779.0%
Oct 10, 2022InitiatedCCanaccord GenuityBuy$28+1,540.8%
May 23, 2022InitiatedHH.C. WainwrightBuy$27+1,482.2%
May 12, 2022InitiatedWWilliam BlairMkt Perform
Jul 13, 2021InitiatedPPiper SandlerOverweight$38+2,126.8%

Peers

Mkt cap
TickerCompanyMkt cap
SANASana Biotechnology Inc690.66M
FATEFate Therapeutics Inc201.20M
VRTXVertex Pharmaceuticals Inc137.96B
CABACabaletta Bio Inc318.18M
KYTXKyverna Therapeutics Inc319.73M
ALLOAllogene Therapeutics Inc309.53M
NKTXNkarta Inc102.88M
CRBUCaribou Biosciences Inc41.87M
CRSPCRISPR Therapeutics AG4.44B
SNYSanofi ADR114.70B

Insider trading

latest 14 of 34
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Carr DouglasSVP Finance & OperationsNov 03 '26Sale1.52266404502,641Nov 05 04:10 PM
Carr DouglasOfficerNov 03 '26Proposed Sale1.52266404Nov 03 03:32 PM
Russotti GregorySee RemarksSep 14 '26Sale1.932,5874,993509,198Sep 15 06:25 PM
Carr DouglasSVP Finance & OperationsSep 14 '26Sale1.931,6583,200502,907Sep 15 06:25 PM
Russotti GregoryOfficerSep 14 '26Proposed Sale1.932,5874,994Sep 14 03:31 PM
Carr DouglasOfficerSep 14 '26Proposed Sale1.931,6583,201Sep 14 03:29 PM
Russotti GregorySee RemarksSep 08 '26Sale2.055341,095511,785Sep 09 04:35 PM
Carr DouglasSVP Finance & OperationsSep 08 '26Sale2.05254521504,565Sep 09 04:34 PM
Russotti GregoryOfficerSep 08 '26Proposed Sale2.055341,094Sep 08 03:10 PM
Carr DouglasSVP Finance & OperationsAug 03 '26Sale1.98275544504,819Aug 05 04:08 PM
Russotti GregorySee RemarksJun 12 '26Sale2.232,5845,767512,319Jun 15 07:57 PM
Carr DouglasSVP Finance & OperationsJun 12 '26Sale2.231,6543,692505,094Jun 15 07:56 PM
Russotti GregoryOfficerJun 12 '26Proposed Sale2.232,5845,768Jun 12 03:35 PM
Russotti GregorySee RemarksJun 08 '26Sale2.115241,106514,903Jun 09 04:10 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
OMFSInvesco Russell 2000 Dynamic Multifactor ETFAUM: 263.85M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 200
  • Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London (GlobeNewswire)
  • Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026 (GlobeNewswire)
  • Century Therapeutics Appoints Joseph Truitt to Board of Directors (GlobeNewswire)
  • Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
  • Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D Clinical & Research Congress 2026 (GlobeNewswire)
  • New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026 (GlobeNewswire)
  • Century Therapeutics Reports First Quarter Financial Results and Business Updates (GlobeNewswire)
  • Century Therapeutics Selected for Oral Presentation of CNTY-813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions (GlobeNewswire)
  • Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates (GlobeNewswire) -8.42%
  • Century Therapeutics to Participate in Upcoming Investor Conferences in March (GlobeNewswire)
  • Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission (Insider Monkey) -5.47%
  • Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +13.24%
  • Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes (GlobeNewswire) +36.15%
  • FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug (Zacks) +44.44%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-12-0.170-0.110-0.1700.000.005
2026Q12026-05-13-0.110-0.158-0.1120.000.005
2025Q42026-03-12-0.250-0.290-0.2190.000.004
2025Q32025-11-13-0.400-0.338-0.3980.000.004
2025Q22025-08-14-0.380-0.376-0.3770.000.006
2025Q12025-05-150.890-0.0080.889109.1641.297
2024Q42025-03-19-0.410-0.410-0.4254.180.787
2024Q32024-11-05-0.370-0.451-0.3690.790.445
2024Q22024-08-08-0.380-0.455-0.3800.770.435
2024Q12024-05-09-0.450-0.513-0.4510.860.215
2023Q42024-03-14-0.660-0.548-0.6580.271.677
2023Q32023-11-09-0.550-0.521-0.5500.151.328
2023Q22023-08-09-0.560-0.544-0.5620.101.148
2023Q12023-05-11-0.530-0.524-0.5331.721.479
2022Q42023-03-17-0.540-0.582-0.5430.522.0010
2022Q32022-11-10-0.530-0.594-0.5302.221.089

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-2.960-3.215-1.7420.000.00
2022FY-2.270-2.308-2.2675.206.69
2023FY-2.300-2.172-2.3042.243.65
2024FY-1.610-1.616-1.6096.593.19
2025FY-0.140-0.180-0.125109.16109.18
2026FY--0.524--0.00
2027FY--0.448--0.00
2028FY--0.360--0.00
2029FY--0.380--0.00
2030FY--0.353--43.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-125000.000.000.00
2026Q3S2026-06-204000.000.000.00
2026Q3S2026-05-135000.000.000.00
2026Q3S2026-04-205000.000.000.00
2026Q3S2026-03-124000.000.000.00
2026Q3S2026-02-243000.000.000.00
2026Q3S2025-11-262000.000.000.00
2026Q3S2025-11-133000.000.000.00
2026Q3S2025-11-113000.000.000.00
2026Q3S2025-11-103000.000.000.00
2026Q3S2025-11-093000.000.000.00
2026Q3S2025-11-083000.000.000.00
2026Q3S2025-11-073000.000.000.00
2026Q3S2025-11-063000.000.000.00

Estimate history

EPS, annual-4.465-0.977-1.742-2.267-2.304-1.609-0.111-0.8969
Period2019202020212022202320242025TTM
EPS, quarterly-0.38-0.369-0.4250.889-0.377-0.398-0.219-0.112-0.168
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0005.1992.2356.589109.1640
Period2019202020212022202320242025TTM
Sales, quarterly0.7710.7914.173109.16400000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual54.82554.82555.00658.47460.33685.83687.519180.547
Period2019202020212022202320242025MRQ
Shares, quarterly84.55284.76285.83686.14686.32286.52887.519180.102180.547
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.00109.166.592.235.200.000.000.00
Cost of Goods Sold Incl. D&A12.3013.1013.3013.0410.074.581.750.25
Gross Profit-12.3096.06-6.71-10.81-4.87-4.58-1.75-0.25
Selling, General and Administrative Excl. Other95.22111.10127.56114.37118.9690.3047.4219.78
Research and Development66.6282.57107.2492.7197.1775.6539.6814.27
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-107.51-15.04-134.27-125.18-123.83-94.88-49.18-20.03
Interest Expense0.000.000.000.541.431.270.380.00
Unusual Expense9.472.233.8721.3610.000.004.72225.95
Net Income Before Taxes-109.86-9.65-124.78-134.79-130.84-95.78-53.58-244.77
Income Taxes-0.07-0.071.791.880.090.040.000.00
Consolidated Net Income-109.79-9.58-126.57-136.67-130.93-95.82-53.58-244.77
Net Income From Continuing Operations-109.79-9.58-126.57-136.67-130.93-95.82-53.58-244.77
Net Income-109.79-9.58-126.57-136.67-130.93-95.82-53.58-244.77
EPS (Recurring)-0.50-0.09-1.57-2.05-2.15-1.74-0.92-1.58
EPS (Basic, Before Extraordinaries)-0.90-0.11-1.61-2.30-2.27-1.74-0.98-4.46
EPS (Diluted)-0.90-0.11-1.61-2.30-2.27-1.74-0.98-4.46
EBITDA-95.22-1.94-120.97-112.14-113.76-90.30-47.42-19.78
Non-Operating Income (Expense)7.137.6213.3612.294.420.380.701.21
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.315.4010.0211.558.433.400.880.15
Price To Sales Ratio-0.7912.0688.1156.99---
Gross Margin-88.00-101.91-483.62-93.71---
Operating Margin--13.78-2,037.81-5,600.94-2,381.82---
Net Margin--8.78-1,920.87-6,115.12-2,518.41---
Shares Outstanding180.5587.5285.8460.3458.4755.0154.8254.82
Market Capitalization304.21304.2185.88198.65302.54866.61837.65-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.00109.164.170.79
Cost of Goods Sold Incl. D&A2.623.003.553.133.203.223.323.30
Gross Profit-2.62-3.00-3.55-3.13-3.20105.940.85-2.51
Selling, General and Administrative Excl. Other24.7122.5022.0225.9931.0832.0134.0632.61
Research and Development16.9814.1016.1419.4023.6623.3626.0623.93
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-27.32-25.50-25.57-29.12-34.2873.94-33.20-35.12
Interest Expense0.000.000.000.000.000.000.00-
Unusual Expense9.21-1.82-4.927.000.38-0.244.08-0.33
Net Income Before Taxes-34.55-21.64-19.24-34.42-32.5476.56-34.30-31.23
Income Taxes0.000.00-0.070.000.000.001.78-0.01
Consolidated Net Income-34.55-21.64-19.17-34.42-32.5476.56-36.07-31.23
Net Income From Continuing Operations-34.55-21.64-19.17-34.42-32.5476.56-36.07-31.23
Net Income-34.55-21.64-19.17-34.42-32.5476.56-36.07-31.23
EPS (Recurring)-0.14-0.12-0.26-0.34-0.370.89-0.39-0.37
EPS (Basic, Before Extraordinaries)-0.17-0.11-0.22-0.40-0.380.89-0.42-0.37
EPS (Diluted)-0.17-0.11-0.22-0.40-0.380.89-0.42-0.37
EBITDA-24.71-22.50-22.02-25.99-31.0877.16-29.88-31.82
Non-Operating Income (Expense)1.982.041.411.702.122.382.993.56
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.951.451.030.892.221.922.102.62
Price To Sales Ratio--0.800.380.420.3613.0253.95
Gross Margin-----97.0520.49-316.81
Operating Margin-----67.73-795.64-4,439.70
Net Margin-----70.13-864.44-3,947.66
Shares Outstanding180.55180.1087.5286.5386.3286.1585.8484.76
Market Capitalization304.21406.1786.9543.0248.1440.9685.88144.86

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments117.91189.29172.74315.50222.8876.5481.54
Short Term Receivables0.671.520.670.780.250.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets2.193.243.593.445.032.262.58
Total Current Assets120.77194.05176.99319.72228.1578.8084.12
Net Property, Plant & Equipment66.1790.8592.08111.7369.8224.782.49
Total Investments and Advances2.3633.5991.0853.83137.632.294.08
Long-Term Note Receivable----0.0031.9070.00
Intangible Assets34.2034.200.000.000.000.000.00
Other Assets0.210.530.541.261.770.910.21
Total Assets223.70353.22360.69486.54437.38138.68160.90
Short Term Debt Incl. Current Port. of LT Debt3.324.871.516.981.650.240.00
Accounts Payable4.773.082.745.457.600.000.00
Other Current Liabilities12.13121.8413.5917.396.4111.872.99
Total Current Liabilities20.23129.7817.8529.8215.6512.112.99
Long Term Debt40.2448.9646.6642.4423.4621.320.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities4.304.37-----
Other Liabilities0.008.74111.44111.552.020.000.00
Total Liabilities64.77191.85175.94183.8141.1433.432.99
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00179.76179.76
Common Equity158.94161.36184.75302.74396.24-74.51-21.86
Total Shareholders Equity158.94161.36184.75302.74396.24105.25157.90
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity158.94161.36184.75302.74396.24105.25157.90
Total Liabilities & Stockholders Equity223.70353.22360.69486.54437.38138.68160.90
Book Value Per Share1.821.883.065.187.20-1.36-0.40
Tangible Book Value Per Share1.431.483.065.187.20-1.36-0.40
Full-Time Employees78150165163170107214
Price to Book Ratio1.310.440.900.902.201.98-
Return on Assets-3.32-35.46-32.26-28.34-33.27-35.77-
Return on Equity-5.98-73.14-56.07-37.46-38.22-40.72-
Return on Invested Capital-4.81-60.18-59.06-37.93-22.83-42.33-155.01
Quick Ratio5.971.509.9210.7214.576.5128.10
Current Ratio5.971.509.9210.7214.576.5128.10

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-109.79-9.58-126.57-136.67-130.93-95.82-53.58-244.77
Depreciation12.3013.1013.3013.0410.074.581.750.25
Other Funds (Non Cash)14.217.2311.5425.9010.975.045.69226.09
Funds from Operations-83.3610.68-100.86-97.73-109.89-86.20-46.13-18.43
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-3.38-114.55-9.289.16123.44-3.584.862.26
Cash from Operating Activities-86.74-103.88-110.14-88.5713.55-89.79-41.27-16.17
Capital Expenditures-1.33-0.85-0.15-13.74-30.60-44.97-9.82-2.46
Net Assets From Acquisitions0.000.00-9.610.000.000.00-4.720.00
Sale of Fixed Assets and Businesses0.060.000.000.000.000.000.0024.17
Purchase or Sale of Investments-46.54108.3557.2474.8717.48-253.37-8.21-41.54
Purchase of Investments-183.28-51.17-119.55-209.03-254.00-330.03-49.86-41.54
Sale Or Maturity of Investments136.74159.52176.79283.90271.4876.6741.650.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-47.82107.5047.4861.13-13.13-298.34-22.76-19.83
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock126.990.1774.560.5227.16383.550.0074.84
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock126.990.1774.560.5227.16383.550.0074.84
Proceedsfrom Stock Options126.390.0074.420.5227.16381.240.0074.84
Issuance or Reduction of Debt, Net0.000.000.00-10.240.000.000.000.00
Change in Long Term Debt0.000.000.00-10.240.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-10.240.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.0034.2347.830.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities126.990.1774.56-9.7227.16417.7747.6974.84
Net Change in Cash-7.573.8011.91-37.1627.5829.65-16.3438.84
Free Cash Flow-88.07-104.72-110.29-102.30-17.05-134.76-51.09-18.63
Preferred Dividends (Cash Flow)-0.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit--0.070.870.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments119.71135.15117.91132.75155.84165.12
Short Term Receivables1.481.370.670.480.630.98
Inventories0.000.000.000.000.000.00
Other Current Assets3.582.512.194.483.703.53
Total Current Assets124.77139.04120.77137.71160.17169.63
Net Property, Plant & Equipment47.9968.5866.1770.2884.3987.76
Total Investments and Advances79.8484.532.362.315.4023.49
Intangible Assets34.2034.2034.2034.2034.2034.20
Other Assets0.210.210.210.210.540.53
Total Assets287.01326.55223.70244.72284.69315.61
Short Term Debt Incl. Current Port. of LT Debt4.044.083.323.774.894.88
Accounts Payable4.823.154.772.623.213.57
Other Current Liabilities6.216.3312.1315.646.856.05
Total Current Liabilities15.0713.5720.2322.0314.9514.50
Long Term Debt34.6343.9440.2441.1946.5947.79
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities4.304.304.304.374.374.37
Other Liabilities0.670.000.000.788.888.50
Total Liabilities54.6661.8164.7768.3774.7975.17
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity232.34264.74158.94176.35209.90240.44
Total Shareholders Equity232.34264.74158.94176.35209.90240.44
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity232.34264.74158.94176.35209.90240.44
Total Liabilities & Stockholders Equity287.01326.55223.70244.72284.69315.61
Book Value Per Share1.291.471.822.042.432.79
Tangible Book Value Per Share1.101.281.431.642.042.39
Full-Time Employees--78---
Price to Book Ratio1.311.240.490.200.200.25
Return on Assets-38.41-33.57-3.32-8.36-6.64-6.61
Return on Equity-49.65-42.67-5.98-14.23-10.78-10.49
Return on Invested Capital-12.94-7.01-9.63-15.82-12.6926.56
Quick Ratio8.2810.255.976.2510.7211.70
Current Ratio8.2810.255.976.2510.7211.70

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-34.55-21.64-19.17-34.43-32.5476.56
Depreciation2.623.003.553.133.203.22
Other Funds (Non Cash)11.41-0.17-3.546.512.451.81
Funds from Operations-20.52-18.81-19.23-24.79-26.8981.59
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.69-6.433.16-0.80-0.70-116.21
Cash from Operating Activities-19.83-25.24-16.08-25.58-27.59-34.62
Capital Expenditures-0.69-0.580.14-0.20-0.32-0.47
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.060.000.000.000.000.00
Purchase or Sale of Investments18.40-112.0322.2224.8732.8628.41
Purchase of Investments-15.97-140.69-15.60-11.02-9.67-14.88
Sale Or Maturity of Investments34.3728.6637.8235.8942.5243.29
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities17.77-112.6122.3624.6732.5427.93
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.31126.620.050.000.000.12
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.31126.620.050.000.000.12
Proceedsfrom Stock Options-0.04126.420.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.31126.620.050.000.000.12
Net Change in Cash-1.76-11.236.34-0.914.95-6.57
Free Cash Flow-20.53-25.83-15.94-25.78-27.91-35.10

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 6.59M 2025: 109.16M
United States2024: 6.59M 2025: 109.16M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3026.04%32.0M123.0M672.20K
2026-10-1523.69%29.1M123.0M624.36K
2026-09-3023.77%29.2M122.9M665.97K
2026-09-1523.88%29.4M122.9M1.06M
2026-08-3124.07%29.5M122.7M1.15M
2026-08-1423.94%29.4M122.7M1.24M
2026-07-3124.41%29.8M122.1M1.25M
2026-07-1523.24%28.4M122.1M1.28M
2026-06-3019.20%23.5M122.1M1.29M
2026-06-1512.62%15.4M122.1M1.13M
2026-05-2910.20%12.5M122.3M1.20M
2026-05-1510.61%12.2M115.1M1.18M
2026-04-3010.50%12.0M114.7M1.25M
2026-04-159.58%11.0M114.5M1.42M
2026-03-319.00%10.3M114.3M1.86M
2026-03-137.55%8.6M114.3M1.86M
2026-02-275.54%6.3M114.2M1.75M
2026-02-134.15%4.7M114.2M1.79M
2026-01-306.30%3.4M53.8M1.93M
2026-01-151.49%0.8M54.3M1.76M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.751.501.1714.83146.001.000.956-0.0090.000
call1.000.401.300.7512.72273.002.000.858-0.0170.001
call1.500.001.000.359.7811660.000.859-0.0430.001
call2.000.001.000.018.05357.000.000.701-0.0390.001
call2.500.000.100.158.9952.000.000.680-0.0450.001
call5.000.000.050.004.2740.000.000.114-0.0120.001
call7.500.003.800.005.3040.000.000.099-0.0130.000
put0.500.000.050.006.2580.000.00-0.045-0.0080.000
put1.000.000.150.003.0720.000.00-0.099-0.0080.000
put1.500.001.000.0011.5020.000.00-0.158-0.0390.001
put2.000.001.000.007.8080.000.00-0.219-0.0480.001
put2.500.301.300.006.3840.000.00-0.734-0.0140.001
put5.001.005.500.000.0000.000.00-0.886-0.0120.001
put7.503.508.000.000.0000.000.00-0.901-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-03144Filing for proposed sale of securities under Rule 144.SEC
2026-10-028-KCurrent report2026-10-02SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-103Initial statement of beneficial ownership of securities2026-09-09SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-06-168-KCurrent report2026-06-15SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-12144Filing for proposed sale of securities under Rule 144.SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11004041
2026-100000
2026-09009.81K4
2026-08005441
2026-070000
2026-060011.09K4
2026-05006181
2026-040000
2026-030044.85K3
2026-02005891
2026-010000
2025-1279.60K24172
2025-1117.33K117.64K3

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.9.84%
TCG Crossover Management, LLC9.84%
Versant Venture Management, LLC6.75%
Deep Track Capital, LP5.25%
Commodore Capital LP4.82%
RTW INVESTMENTS, LP4.82%
Venrock Adviser, LLC4.82%
BlackRock, Inc.4.49%
VANGUARD CAPITAL MANAGEMENT LLC3.16%
BALYASNY ASSET MANAGEMENT L.P.3.06%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.41%
iShares Russell 2000 ETF1.61%
Fidelity Small Cap Index Fund0.74%
VANGUARD EXTENDED MARKET INDEX FUND0.68%
iShares Russell 2000 Value ETF0.61%
VANGUARD RUSSELL 2000 INDEX FUND0.39%
Small Cap Value Fund0.30%
Fidelity Extended Market Index Fund0.29%
iShares Micro-Cap ETF0.23%
Schwab Small-Cap Index Fund0.17%

OakChart. IPSC. Cached 15 minutes.